$5.40
+0.13 (+2.47%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TLSI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 1 tracked-famous manager (AQR CAPITAL MANAGEMENT LLC) · FINRA short interest 22.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic AdenocarcinomaNCT05607953Phase 1 - To determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) of SD-101 administered alone via PRVI.Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: SD-101 · Biological: anti-PD-1 | Locally Advanced Pancreatic Adenocarcinoma | 60 | Sep 2027 | ≤ 407 d | 2025-07-04 |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsNCT05220722Phase 1b: To Determine the Safety of SD-101 Alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and IpilimumabOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns. | Drug: SD-101 · Biological: Pembrolizumab, Nivolumab, Ipilimumab | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 23 | 2024-07-31actual | — | 2025-10-23 |
| Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaNCT04935229Phase 1: To Determine the Safety of SD-101 Alone, in Combination with Nivolumab, and in Combination with Both Nivolumab and IpilimumabOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns. | Drug: SD-101 · Biological: Nivolumab, Ipilimumab, Nivolumab and Relatlimab | Metastatic Uveal Melanoma in the Liver | 67 | 2024-07-17actual | — | 2025-10-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19